Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoVax with Checkpoint Inhibitors in Newly Diagnosed Glioblastoma
NCT03422094Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2018
- Primary completion
- Apr 2020
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of NeoVax in glioblastoma (GBM) (5 arms), sponsored by Washington University School of Medicine. Primary endpoints: Dose-Limiting Toxicity Rate up to 90 days, Feasibility of Neoantigen Identification at 14 weeks and 2 more. Started Oct 2018; status: terminated.
02
Drugs
NeoVax
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03422094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422094.